These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. Hsu CC; Liu KH; Chang PH; Chen PT; Hung CY; Hsueh SW; Yeh KY; Chen YY; Lu CH; Hung YS; Chou WC J Gastroenterol Hepatol; 2020 Oct; 35(10):1694-1703. PubMed ID: 31711261 [TBL] [Abstract][Full Text] [Related]
7. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers? Adhikaree J; Madhusudan S Med Oncol; 2014 Jul; 31(7):46. PubMed ID: 24913810 [TBL] [Abstract][Full Text] [Related]
8. [Prediction model for survival in patients with biliary tract cancer: a development and validation study]. Han L; Cui P; Tang MS; Zhang M; Cui HJ; Zeng ZQ; Chen SY; Liu SS; Song B; Gu DQ; Wang X; Zhang B Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1461-1469. PubMed ID: 31838822 [No Abstract] [Full Text] [Related]
9. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436 [TBL] [Abstract][Full Text] [Related]
11. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L; Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966 [TBL] [Abstract][Full Text] [Related]
12. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710 [TBL] [Abstract][Full Text] [Related]
13. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data. Ying J; Chen J Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533 [TBL] [Abstract][Full Text] [Related]
14. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Fornaro L; Cereda S; Aprile G; Di Girolamo S; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Vivaldi C; Belli C; Bergamo F; Lutrino SE; Filippi R; Russano M; Vaccaro V; Brunetti AE; Rotella V; Falcone A; Barbera MA; Corbelli J; Fasola G; Aglietta M; Zagonel V; Reni M; Vasile E; Brandi G Br J Cancer; 2014 Apr; 110(9):2165-9. PubMed ID: 24714745 [TBL] [Abstract][Full Text] [Related]
15. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy. Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425 [TBL] [Abstract][Full Text] [Related]
16. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Moik F; Riedl JM; Winder T; Terbuch A; Rossmann CH; Szkandera J; Bauernhofer T; Kasparek AK; Schaberl-Moser R; Reicher A; Prinz F; Pichler M; Stöger H; Stotz M; Gerger A; Posch F Sci Rep; 2019 Apr; 9(1):5548. PubMed ID: 30944390 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Saisho T; Okusaka T; Ueno H; Morizane C; Okada S Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750 [TBL] [Abstract][Full Text] [Related]
18. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer. Li H; Zhao T; Ji X; Liang S; Wang Z; Yang Y; Yin J; Wang R Tumour Biol; 2016 Mar; 37(3):3535-42. PubMed ID: 26453118 [TBL] [Abstract][Full Text] [Related]
19. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. Moriwaki T; Ishige K; Araki M; Yoshida S; Nishi M; Sato M; Yamada T; Yamamoto Y; Ozeki M; Ishida H; Yamaguchi T; Matsuda K; Murashita T; Abei M; Hyodo I Med Oncol; 2014 Nov; 31(11):287. PubMed ID: 25316268 [TBL] [Abstract][Full Text] [Related]
20. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study. Kus T; Aktas G; Kalender ME; Sevinc A; Camci C J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]